Company*
(Country;  Symbol)
Company*
(Country;  Symbol)
Type/Product Area Terms/Details (Date)

JUNE
 
Access Pharmaceuticals Inc. (AMEX:AKC) Two undisclosed biopharmaceutical companies Evaluation agreements for its Cobalamin oral drugdelivery technology Both companies plan to evaluate Access' oral insulin product in preclinical modelsas a prerequisite to entering licensing discussions (6/17)
 
Atox Bio Ltd.* (subsidiary of Yissum Research Development Company Ltd.; Israel) Fast-Track Drugs & Biologics LLC* Joint research and development program to continue the development of Atox Bio's mechanism-based immunomodulator peptide, AB103, for the treatment of sepsis and septic shock The program was awarded $575,000 from the Israel-U.S. Binational Industrial Research and Development Fund (6/24)
 
BayHill Therapeutics Inc.*  Genentech Inc. (part of Roche AG) Worldwide development and commercialization agreement for BHT-3021 for Type I diabetes The deal could mean more than $350M for Bayhill, including $25M up front in cash and equity (6/10)
 
Bio-Bridge Sciences Inc. (OTC BB:BGES) JR Scientific Inc.* and several other investors Joint venture contract for a new cell culture medium joint venture in Beijing The registered capital of the new venture will be RMB10M ($1.5M); Bio-Bridge Science will invest RMB5.1M in cash for a 51% controlling interest, and JRS will provide technology for a 15% ownership interest (6/10)
 
Cerulean Pharma Inc.* Calando Pharmaceuticals Inc.* Exclusive, worldwide license agreement for Calando's cyclodextrin co-polymer-based drug delivery technology to develop and commercialize products Calando will receive an up-front payment as well as development and sales milestones and sales royalties, but financial terms were not disclosed (6/24)
 
Cordex Pharma Inc. (OTC BB:CDXP) Clinical Trials International LLC* Agreement for certain ex-U.S. development and commercialization rights to ATPotent CTI gets exclusive rights in the European Union, Russia and the Ukraine and plans to initiate a proof-of concept study this year (6/22)
 
Exosome Diagnostics Inc.*  DxS Ltd.* (UK) Collaboration on the development of blood-based companion diagnostics for key cancer gene mutations They will use DxS' Scorpions real-time PCR Mutation Test Kits in conjunction with ExosomeDX's xOS technology (6/23)
 
Flamel Technologies SA (France; FLML) Undisclosed companies Feasibility agreements to apply its Medusa platform with two companies One program is designed to deliver a controlled release of a marketed hormone; the other is a Medusa formulation of a therapeutic peptide (6/25)
 
Jubilant Organosys Ltd.* (India) Endo Pharmaceuticals Holdings Inc. (ENDP) Oncology discovery and development collaboration Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization; Jubilant will receive research funding and milestones and royalties (6/11)
 
Juvaris BioTherapeutics Inc.* Antigen Discovery Inc.* Agreement for access to high-throughput protein microarray screening system to discover novel disease-specific antigens to fuel Juvaris' vaccine pipeline Juvaris will sponsor research for multiple disease targets and pay ADI undisclosed up-front payments, development milestones and royalties (6/30)
 
Ligand Pharmaceuticals Inc. (LGND) ParinGenix Inc.* Exclusive license agreement under which ParinGenix was granted exclusive license rights to three issued U.S. patents relating to certain desulfated heparin compounds Ligand will receive an up-front payment as well as a royalty on net sales in the U.S. by ParinGenix of 2-O, 3-O desulfated heparin products (6/25)
 
Mylan Inc. (MYL) Biocon Ltd. (India; Bombay: BIOCON) Agreement to collaborate on the development, manufacturing, supply and commercialization of generic biologics The firms will share costs with Mylan retaining exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand and in the European Union (6/29)
 
NeoStem Inc. (AMEX:NBS) Enhance BioMedical Holdings Ltd.* 10-year agreement to develop a Stem Cell Collection and Treatment Network using NeoStem's adult stem cell technologies in Shanghai, Taiwan and other Chinese provinces Enhance BioMedical holds exclusive rights to NeoStem's adult stem cell technologies to provide adult stem cell services and therapies in the Asian territory (6/15)
 
Novation Pharmaceuticals Inc.* (Canada) OTC Cancer Therapeutics LLC (Australia; BB:CTHP) Collaboration to identify small molecules targeting c-myc and hSSB1 for cancer Novation will own resulting compounds for c-myc and CTx will own those targeting hSSB1 (6/12)
 
OPKO Health Inc. (AMEX:OPK) Sorrento Therapeutics Inc.* Agreement under which OPKO invested in Sorrento in exchange for one-third of  the company's shares and an exclusive license to its antibody library for ophthalmology therapeutics The amount of the investment was not disclosed (6/11)
 
Pharnext* Ipsen SA (France; Paris:IPN) Licensing deal for Pharnext's lead program in the chronic neuromuscular disease, Charcot-Marie-Tooth The deal is valued at $126.1M, including up-front convertible bonds, as well as mile-stones and royalties (6/15)
 
Xcellerex Inc.* Crucell NV (the Netherlands; CRXL) Agreement for Crucell to acquire a FlexFactory bio-production line and multiple XDR single-use bioreactors to expand the capacity and flexibility of its manufacturing capabilities Terms were not disclosed (6/17)
 
JULY
 
Acorda Therapeutics Inc. (ACOR)  Biogen Idec Inc. (BIIB) Licensing agreement for rights to Fampridine-SR, designed to improve walking ability in multiple sclerosis patients The deal includes $110M up front and up to $400M in milestones, plus tiered, double-digit royalties on sales outside the U.S. (7/1)
 
Ambrilia Biopharma Inc. (Canada; TSX: AMB) Kotinos Pharmaceuticals Inc.* Patent and technology purchase agreement for Kotinos to acquire Ambrilia's prostate cancer therapeutic PCK3145 and related assets Ambrilia is eligible to receive up to $15M in development and sales milestones, including an up-front payment of $200,000, and double-digit royalties on product net sales (7/17)
 
Archemix Corp.*   Dicerna Pharmaceuticals Inc.* Collaboration on aptamer-dicer substrate RNA therapeutics aimed at leveraging the intracellular delivery capabilities of Archemix's aptamers and the gene silencing of Dicerna's DsiRNA molecules Both companies are investing resources and will work together on R&D activities; the deal includes an option for Dicerna to obtain exclusive rights for further development of products generated during the collaboration (7/21)
 
Asuragen Inc.* Biogen Idec Inc. (BIIB) Agreement to identify a potential companion diagnostic test that may be used to select patients likely to respond to a Biogen Idec therapeutic candidate in clinical development The goal is to help physicians identify patients who will benefit from specific cancer treatments (7/20)
 
Benitec Ltd. (Australia; ASX:BLT) Biomics Biotechnologies Co. Ltd.* (China) Memorandum of understanding to collaborate on a DNA-directed or vector-expressed RNAi to treat chronic hepatitis B virus infection They will develop a project plan for target identification and validation, and will then begin preclinical testing (7/14)
 
Bioniche Life Sciences Inc. (Canada; TSX:BNC) Endo Pharmaceuticals Inc. (ENDP) Urology drug deal under which Endo will develop and market Bioniche's Phase III bladder cancer product, Urocidin The deal is worth $130M, including $20M up front and up to $110M in potential milestone payments (7/10)
 
Catalyst Biosciences Inc.*  MedImmune (unit of Astra-Zeneca plc; UK; LSE:MDI) Agreement to develop drug candidates against two targets, one of which will address inflammatory and autoimmune diseases Catalyst will receive undisclosed up-front licensing fees, full-time employee support and milestone payments totaling up to $195M, excluding royalties (7/7)
 
Champions Biotechnology Inc. (OTC BB: CSBR) Do-Coop Technologies Ltd.* (Israel) Collaboration to develop a more soluble form of  SG410 Do-Coop will receive development milestones and royalties (7/16)
 
Commonwealth Biotechnologies Inc. (CBTE)  Bostwick Laboratories Inc.* Agreement for the sale of CBI's Fairfax Identity Laboratories and CBI Services divisions It was sold for $1.075M in cash and royalty payments to CBI over five years (7/21)
 
Cornerstone Therapeutics Inc. (CRTX) Oscient Pharmaceuticals Corp. (OSCI) Agreement giving Cornerstone the rights to Factive in North America and some parts of Europe Oscient gains $5M and will receive a royalty on sales of the antibiotic; Cornerstone also gets the Factive inventory (7/14)
 
DxS Ltd.* (UK) Epigenomics AG (Germany; FSE:ECX) Cross-licensing agreement enabling both companies to develop and commercialize in vitro diagnostic products based on DNA methylation Financial terms of the agreement were not disclosed (7/20)
 
Evotec AG

(Germany;

EVTC)
Cubist

Pharmaceuticals

Inc. (CBST)
Research agreement for

fragment-based drug

discovery
Cubist will use Evotec's fragment screen-

ing technology EVOlution to complement

discovery research efforts in two of its

antibacterials program (7/14)

 
Horizon Discovery* (UK) DxS Ltd.* (UK) Partnership in which Horizon will develop a panel of human isogenic cell models that recapitulate key drug sensitivity and resistance mechanisms in cancer patients that will be used to further develop DxS TheraScreen range of  clinical diagnostic kits Horizon will use a gene-engineering technology called GENESIS to generate a range of mutant and normal, or X-MAN, cell lines as a source of genetically defined human DNA that will be used to assess the performance of DxS' TheraScreen KRAS mutation kits (7/21)
 
Ikaria Holdings Inc.*  BioLineRx Ltd. (Israel; TASE:BLRX) Licensing agreement for BL-1040, which is in Phase I/II to treat damaged heart tissue following a heart  attack The deal is worth $282.5M and includes up-front and milestone payments, plus royalties (7/6)
 
ImmunoVaccine Technologies Inc.* (Canada) Immunotope Inc.*

 

Agreement to exclusively license seven cancer antigens The antigens specifically target breast, ovarian and prostate cancers (7/14)
 
InNexus Biotechnology Inc. (Canada; OTC BB:IXSBF) Genhelix Bio-pharmaceutical Co.* (Spain) Agreement for a planned strategic collaboration to focus on developing novel antibodies engineered with inNexus' DXL technology InNexus will conduct preclinical development for a DXL therapeutic against an undisclosed target, with Genhelix providing GMP production and commercial manufacturing (7/10)
 
MiRagen Therapeutics Inc.* Archemix Corp.* Collaboration on conjugated aptamer-microRNA therapies capable of intracellular delivery and subsequent microRNA targeting The companies will pursue research and development efforts, and both will contribute resources under the agreement,  which allows miRagen to negotiate for exclusive rights to further develop and commercialize certain aptamer-microRNA therapeutics generated (7/23)
 
Morphotek Inc. (subsidiary of Eisai Corp. of North America; FSE:EII) Synageva BioPharma Corp.* Research collaboration agreement to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease Synageva will use its Synageva Expression Platform technology and its expertise to produce and develop a therapeutic mono-clonal antibody (7/1)
 
Morphotek Inc. (subsidiary of Eisai Corp. of North America; FSE:EII) Cancer Innovations Inc.* Option agreement to evaluate monoclonal antibodies targeting certain tumor-associated proteins Financial terms were not disclosed (7/15)
 
OxiGene Inc. (OXGN)  Symphony VIDA Inc.* Exercised option for OxiGene to acquire all the equity of Symphony VIDA, the joint venture established in October 2008 as a funding vehicle to support development of early stage drug OXi4503 in cancer and Zybrestat in ophthalmology indications OxiGene is issuing 6M shares to Symphony Capital Partners LP, valuing the deal at about $12.5M (7/6)
 
Peregrine Pharmaceuticals Inc. (PPHM) Affitech AS (Norway; CSE:AFFI) Licensing agreement for Peregrine's preclinical anti-VEGF antibody program Peregrine will receive an up-front payment, research fees and future milestone payments (7/22)
 
Proteome Sciences plc (UK; LSE:PRM) Millipore Corp. (NYSE:MIL) Exclusive licensing agreement to develop products to advance the study of Alzheimer's disease Millipore will develop Luminex bead-based multiplex immunoassays to measure Proteome's Alzheimer's disease biomarkers (7/6)
 
Xbrane Bioscience AB* (Sweden) New England Biolabs Inc.* Global license agreement for a novel strain ofEscherichia coli, which is engineered for the optimal expression of membrane proteins and other proteins that are difficult to produce; it is known as the Lemo System Terms were not disclosed, but the deal has the potential to generate significant license revenues for Xbrane (7/14)

Notes:

* Private companies are indicated with an asterisk. Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TASE = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange.